Good MorningThe major indices were mostly flat on Tuesday as earnings season kicks into high gear. The onslaught of reports was met with little fanfare although it is still early in the season. On balance, more companies than average are beating their consensus earnings estimates although by a smaller margin than expected. If this trend persists through the end of the reporting season the market may find itself stuck in a trading range until a new catalyst emerges.
Reports that may move the market on Wednesday include Microsoft, Starbucks, AMD and Apple. Apple is slated to report after the bell and could be a turning point for the market. The company’s earnings estimates have been moving steadily higher since early summer and may be hard to beat. Anything less than a stunning report may be too little to keep share prices trading at all-time high levels.
Featured: See the Daily 10AM setup for 4PM payouts (Ad) 
|
Tech | | | A head-scratching David and Goliath story is playing out on Wall Street over the stock price of a money-losing video game retailer.
An army of smaller-pocketed, optimistic investors is throwing dollars and buy orders at the stock of GameStop — in direct opposition to a group of wealt... Read the Full Story |
|
|
Tech | | | The U.S.-Chinese trade war isn’t going away under President Joe Biden.
Biden won’t confront Beijing right away, economists say, because he wants to focus on the coronavirus and the economy. But he looks set to renew pressure over trade and technology grievances that prompted Presiden... Read the Full Story |
|
Markets | | |
In what many analysts are calling a frothy market, Johnson & Johnson (NYSE:JNJ) must be wondering what gives? The iconic big pharma company is being held to a mighty high standard. It’s true that Johnson & Johnson is supposed to be a steady Eddie stock without a lot of volatility. Bu... Read the Full Story |
|
|
Markets | | | Shares have opened higher in Europe after a broad retreat in Asia on renewed worries that troubles with COVID vaccine rollouts and the spread of new variants of coronavirus might delay a recovery from the pandemic Read the Full Story |
|
Markets | | | Shares fell in Asia on Tuesday on renewed worries that troubles with COVID vaccine rollouts and the spread of new variants of coronavirus might delay a recovery from the pandemic.
Hong Kong led other regional markets lower, dropping 2.4% to 29,440.03.
Traders are keepi... Read the Full Story |
|
|
Markets | | | Semiconductor chip maker Taiwan Semiconductor Manufacturing Company (NYSE: TSM) stock has been on a near parabolic ascent as the fabless trend continues to gain momentum. Taiwan Semi is the world’s largest chip maker where some of the largest technology companies outsource the manufacturing of their chips. Read the Full Story |
|
Stocks | | | U.S. major automobile manufacturer Ford Motor Company (NYSE: F) stock has recently rallied on the electric vehicle (EV) momentum that has finally flowed from first movers like Tesla (NASDAQ:TSLA) into the traditional U.S. automakers lead by General Motors (NYSE: GM). Shares up over 25% year-to-date ... Read the Full Story |
|
Politics | | | Chancellor Angela Merkel’s chief of staff has floated the idea of Germany suspending rules to prevent the government running up new debt for several years as Europe’s biggest economy digests the impact of the coronavirus pandemic Read the Full Story |
|
Stocks | | | The stocks we are highlighting today are not only well-positioned for the 2021 rebound but also pay dividends. Better, they are all dividend growers with above-average yields and a positive outlook for future increases.
Read the Full Story |
|
Markets | | | If you are looking for a single stock to ride out the post-pandemic boom then H.B. Fuller Company (NYSE:FUL) may be it. The company manufactures specialty chemicals worldwide which doesn’t sound all that exciting Read the Full Story |
|
The Early Bird Stock Of The Day Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. | | View Today's Stock Pick |
|
